Development of an immunoblotting assay for serodiagnosis of *Burkholderia mallei* infection: the whole-cell proteome-based paradigm

Sajjad Yazdansetad¹, Nader Mosavari², Keyvan Tadayon³, Iraj Mehregan⁴

¹Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
²Department of Tuberculin and Mallein, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
³Department of Veterinary Aerobic Bacterial Vaccines, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran

Received: March 2019, Accepted: May 2019

ABSTRACT

Background and Objectives: *Burkholderia mallei* is the leading cause of glanders, a highly transmittable and an OIE-notifiable disease of equidae. Despite the importance of *B. mallei*, little is known about serodiagnosis of glanders. The present study aimed to develop an immunoblotting assay based on whole-cell proteome of *B. mallei* to enable accurate serodiagnosis of glanders.

Materials and Methods: Three farm horses were subcutaneously immunized with a crude suspension (10⁶ cfu/ml) of heat-inactivated *B. mallei* formulated with incomplete Freund's adjuvant (IFA) to achieve a hyperimmune sera panel. The immunization was done for 1, 14 and 28 days with 1 dose of 1 ml antigen containing 10⁶ cfu/ml. The hyperimmunity of sera was confirmed by CFT. *B. mallei* whole-cell proteome was prepared through sonication and the protein content was visualized by SDS-PAGE and quantified by Western blot using HRP-conjugated rabbit anti-horse IgG. A comprehensive set of positive and negative horse sera validated the test.

Results: A ladder pattern of the *B. mallei* immunoreactive antigens was seen within the region of 20-90 kDa clearly and the immunoblot was scored positive, while no reaction was seen for the negative sera. The Western blot assay indicated a noticeably higher diagnostic specificity for positive or negative sera of glanders.

Conclusion: The whole-cell proteome-based immunoblot proved reliable and straightforward in our study. The prepared antigen was adaptable for application in immunoblotting. We assumed this improved immunoblotting system provides appropriate sensitivity and also specificity expected in serodiagnosis of glanders in endemic areas and typically in less-developed countries.

Keywords: *Burkholderia mallei*; Immunoblotting; Glanders; Whole-cell proteome; Serodiagnosis
INTRODUCTION

*Burkholderia mallei*, a Gram-negative bacillus, is the causative agent of the febrile disease known as glanders, a pulmonary disease, and a facultative intracellular pathogen mostly of equidae (1, 2). Glanders is a highly contagious and zoonotic disease primarily affecting solipeds (i.e., horses, mules, and donkeys) (3). Generally, glanders in horse tends to be a chronic disease but in other equidae (i.e., mule, zebra, and donkey) the disease has an acute nature (3, 4). In equids, glanders is transmitted by oro-nasal mucous membrane invasion and inhalation routes (5). The common symptoms of glanders include nasal discharge (mucopurulent), lung lesions and nodules involving the liver and spleen (3).

Humans are accidental hosts for glanders and naturally acquired glanders is sporadic. Veterinarians, farmers, and horsekeepers are professionals who are most likely to acquire the disease through their likely close proximity to diseased animals (1, 4). In humans, *B. mallei* can be directly transmitted by invasion of nasal, conjunctival and oral mucous membranes; abraded or lacerated skin and by inhalation into the lungs. The manifestations correlate with the route of infection and the disease can be either of an acute or chronic nature (4). Human glanders cases have previously been reported from Austria, Cameroon, Curacao, Sri Lanka, Turkey and the USA, but human epidemic has not been recorded (3). The once globally scattered disease is now endemic mostly in Africa, Asia, Middle East, as well as Central and South America (2, 6). The disease recently qualified as re-emergent due to the increased number of cases reported in several parts of the world during the last 20 years (3). Glanders has remained in Iran over more than 60 years by having neighboring countries located in the endemic disease focus (7).

*B. mallei* has many intrinsic antibiotic resistances (e.g., earlier beta-lactams, colistin, fluoroquinolones, macrolides and aminoglycosides) (8). There is no globally-accepted chemical treatment regimen in human cases while suspicious/diseased animals are normally euthanized fearing dissemination of the disease (4). Glanders has a case fatality rate of 95% in untreated humans with septicaemia and 50% even after administration of antibiotic therapy (9). *B. mallei* is a category B classified biotreat agent by Center for Disease Control (CDC) and a listed pathogen by Biological Weapons Convention on the grounds of its flexibility to be weaponized (4, 10). In fact, *B. mallei* was among the few biological agents used in the World Wars I and II and is one of the first examples of the use of bacteria in warfare (2, 3, 11). The severe and debilitating diseases caused by these intracellular pathogens are difficult to diagnose, and there are currently no commercially available vaccines for either human or veterinary use (10).

The traditional method of diagnosis of glanders is the mallein intradermal test where a small volume of *B. mallei* culture extract (e.g. 0.1 ml) is administrated into the lower eyelid of the suspected equid and reactions are assayed after specific time (12). Poor efficiency and indecisive results in acute and progressed cases of the disease along with cross-reactivity with the other serological tests seriously lower the clinical performance of this test (13). The serological tests, including complement fixation test (CFT), enzyme-linked immunosorbent assays (ELISA), Rose Bengal plate agglutination test (RBPT), indirect fluorescent antibody test (IFAT), indirect hemagglutination test (IHAT), and counter immunoelectrophoresis test (CIET) have been used for diagnosis of glanders where there is technically no flawless method of choice (14). CFT however, is currently the most widely used test in international trade of equines and is recommended by the World Organisation of Animal Health (OIE) (12) though some limitations such as false positive/negative results have been noticed (5, 15, 16). The CFT is a labor-intensive and time-consuming test with sensitivity of 90-95%, and a questionable specificity (5). There is, therefore, room for development of an immunoblotting-based method providing high specificity. Given that the present study was conducted to assess suitability of immunodominant protein antigens screened from whole-cell protein content of *B. mallei* for glanders serodiagnosis. Technical issues in preparation, selection, extraction and characterization of whole-cell protein repertoire obtained from Iranian isolates of the bacterium were addressed.

MATERIALS AND METHODS

Bacterial strains, growth conditions, and antigen preparation. The smooth, virulent laboratory strain of *B. mallei* Razi 325 (Razi Type Culture Collection; RTCC 2375) was used as a control strain. This non-native strain has been employed for the
production line of the mallein at the Razi Vaccine and Serum Research Institute, IR, Iran and was kindly provided by the Swedish cooperative laboratory in 1956. Furthermore, we have isolated 4 new strains of *B. mallei* (Tiger, isolated from tiger in 2010; Kordan, isolated from mare in 2013; Oshnavieh, isolated from mule in 2014; and Semirom, isolated from mare in 2016) regarding the endemic disease in Iran over a 7-year period ranging from 2010 to 2016. Considering the Biosafety Level 3 (BSL-3) facility, the *B. mallei* strains were aerobically cultured in nutrient broth supplemented with glycerol 4% for 48 h at 37°C. Whole-cell proteome of bacterial isolates was extracted as follow: concisely, the culture pellet was centrifugation at 9,000 × g for 15 min at 4°C then washed thrice with ice-cold phosphate buffered saline (0.01 M PBS, pH 7.2). The pellet was resuspended in PBS containing 1 mM phenylmethane sulfonyl fluoride (PMSF) and sonicated on ice at 90 amplitude for 5 cycles of 1 min pulsing with 1 min rests between the pulses (Hilscher-Ultrasound Technology, PN-66-NNN, Germany) then centrifuged at 9000 × g for 10 min. The supernatant was treated with 1 ml lysis buffer (Urea 8 M, Tris-Hcl 10 mM, NaH,PO4, 100 mM, EDTA 1 M, SDS 1%). The supernatant was precipitated with tricarboxylic acid (TCA) (Merck, Germany). The washed pellet was resuspended in PBS (0.01 M, pH 7.2) (5). Total protein concentration was evaluated using the Bradford method by measuring the absorbance at 595 nm (UV/Vis spectrophotometer 6320D, Jenway, UK) using bovine serum albumin (BSA) as the standard.

**Hyperimmune sera production in rabbit and horse.** A male albino rabbit with a weight of about 1.5 kg and 6 months old was immunized with a 10⁶ cfu/ml crude suspension of heat-inactivated *B. mallei*. The same condition was applied for *Pseudomonas aeruginosa* ATCC® 27853 and *Burkholderia pseudomallei* ATCC® 23343 as the control strains. The immunization was done intracutaneously with 10 doses of 0.5 ml antigen containing 10⁶ cfu/ml in three days of 0, 3 and 7. The next step immunization was continued in days of 14, 21, 28, 35 and 42 in the ear marginal vein by 0.5 ml antigen as described above. The hyperimmune serum was obtained 7 weeks followed by the first immunization.

The immunization of 3 horses was subcutaneously carried out with a crude suspension (10⁶ cfu/ml) of heat-inactivated *B. mallei* formulated with incomplete Freund’s adjuvant (IFA) (Invivogen, USA) to achieve a hyperimmune sera panel. The immunization was done for 1, 14, 28 days with 1 dose of 1 ml antigen containing 10⁶ cfu/ml. The titer was parallel analyzed with CFT and Western blot assay parallely using the homologous antigen twice-weekly and for 10 weeks followed by the first step of immunization (15). *Burkholderia pseudomallei* ATCC® 23343 was used as the control strain. All the animal experiments were authorized by the ethics committee of Razi Vaccine & Serum Research Institute, Karaj, Iran.

**Serum samples collection, enzyme-linked immunosorbent assay (ELISA), and complement fixation test (CFT).** A total of 121 sera samples were obtained from different horse populations in various geographical areas of Iran from 2016 to 2018. The sera samples were parallely monitored by ELISA and CFT for glands according to the instructions of the OIE Manual of Diagnostic tests and Vaccines for Terrestrial Animals. Appropriate antigen concentration and serum dilution was optimized by checker-board titration method using glandes positive and negative control sera. Indirect ELISA was launched in 96-well microplates (Corning® Round-bottom ELISA Microplates, Singapore) coated with 10 μg/ml *B. mallei* LPS antigen in 0.05 M carbonate-bicarbonate buffer, pH 9.6 at 4°C overnight. The plates were twice washed with PBS-T, pH 7.2 (0.01 M PBS, 0.05% tween 20) and blocked with 2.5% skimmed milk in PBS-T for 2 h at 37°C. Test sera diluted 1:200 in blocking buffer was appended in duplicate wells for 1 h at 37°C. Then, the wells were washed five times with PBS-T. Rabbit anti-horse (IgG) antibodies conjugated to horseradish peroxidase (HRP) diluted 1:10,000 were added to the wells and incubated for 1 h at 37°C. After washing five times with PBS-T, the plate was developed in the dark for 10 min with TMB (3,3',5,5'-Tetramethylbenzidine) chromogenic substrate. The reaction was stopped by addition of 2.5 M H₂SO₄ and absorbance was measured at 492 nm in an ELISA plate reader (BioTek 800 TS, USA). Cutoff value for indirect ELISA was determined by 15 randomly assigned glands-negative sera samples according to the above-described method. The cutoff optical density at 492 nm was measured by the addition of 2 standard deviations (SDs) to the mean OD₄₉₂ of the sera samples, and test samples with an OD₄₉₂ greater than the cutoff were preserved as positive.
CFT was carried out with the standard method as described by the OIE. Briefly, equine sera were diluted 1:5 in veronal buffered saline (VBS) (bio-PLUS™, USA) containing 0.1% gelatin. The diluted sera were inactivated for 30 min at 58°C. Twofold dilutions of the sera were prepared using veronal buffer in 96-well round-bottom microtiter plates. Serum, complement, and antigen were gently mixed and incubated for 1 h at 37°C. A 2.5% suspension of sensitized washed sheep red blood cells was added. Plates were incubated for 1 h at 37°C and then centrifuged for 5 min at 600 × g. Serum haemolysis at the 1:5 dilution was considered as negative. The controls of the positive, negative, complement/anti-complement, antigen, and haemolytic system were remarked (12).

**Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).** The protein repertoire of *B. mallei* strains was separated on denaturing 6-12% polyacrylamide gradient gels for 15 h at 25 V according to the Laemmli method. Coomassie brilliant blue G-250 was used for staining and the molecular mass of the proteins was estimated using protein standards.

**Western blotting.** The prepared antigens of the *B. mallei* native strains were equally mixed for further investigation of immunoblotting. A replicate gel was transferred to polyvinylidene difluoride (PVDF) membrane (Roche Mannheim, Germany) for 2 h at 300 V. Prior to use, the membrane was activated by soaking in methanol for 20 seconds. The membrane was blocked with 5% BSA for overnight. After being washed with TBS-T (Tris-HCl 20 mM, NaCl 150 mM, pH 7.5-Tween 0.05%) three times, the membrane was cut into thin strips, then incubated with a 1:200 dilution of equine/rabbit sera as the primary antibody, followed by washed three times with TBS-T, and a 1:10,000 dilution of HRP-conjugated rabbit anti-horse IgG as the secondary antibody (Amersham BioSciences, UK) in TBS-T for 2 h. The signals were followed by chemiluminescent 3,3'-diaminobenzidine (DAB) (Sigma- Aldrich, USA) and H₂O₂ as the substrate.

**Statistical analysis.** McNemar’s test by the Prism 8.0 statistics tool was used to interpret of the sensitivity, specificity, and positive and negative predictive values of the immune assay methods.

**RESULTS**

**Protein profile of Iranian isolates of *B. mallei*.** Two culture conditions were considered for the *B. mallei* native strain growth. Regarding the glycerol as the key factor on the growth of *B. mallei*, once the bacterial strains were cultured in nutrient broth supplemented with glycerol 0.5% and once again increased with glycerol 4%. No difference was seen at protein expression level by SDS-PAGE analysis in both conditions (Fig. 1). The protein concentration was measured by absorption at 280 nm for each preparation and was estimated at 1.5 mg/ml on average.

**ELISA, CFT and Western blot assay.** A total of 13 out of 121 sera samples were positive by indirect ELISA regarding the cutoff ODₐ₀ (mean ODₐ₀±2 SDs). One false negative and 2 false positive were found by the indirect ELISA. The sensitivity and specificity of indirect ELISA were evaluated (91.66%; 95% CI 89.1-94.3) and (98.21%; 95% CI 95.3-99.0), respectively. The positive predictive value (PPV) and nega-
tive predictive value (NPV) were estimated (84.61%; 95% CI 78.3–89.4) and (99.09%; 95% CI 96.4–99.7), respectively. CFT assay indicated that 12 out of 121 sera were positive with sensitivity and specificity of (91.66%; 95% CI 89.1–94.3) and (99.09%; 95% CI 96.4–99.7), respectively. Only 1 false negative and 1 false positive were found by the CFT. The PPV and NPV of CFT were estimated (91.66%; 95% CI 89.1–94.3) and (99.09%; 95% CI 96.4–99.7), respectively. Further, sera with suspicious results in indirect ELISA and anticomplementary activity in CFT were re-tested by Western blotting. 11 ELISA and CFT-positive sera were assayed by Western blot showing ladder-like bands pattern of immunoreactive proteins and were counted positive. Although, 110 out of 121 sera were scored true negative by the Western blot assay. The immunoproteomic strategy using specific immunoreactive proteins of B. mallei was applied for the serodiagnosis of glanders with the high sensitivity and specificity of 100% (95% CI). Furthermore, it seems that the most immunoreactive proteins of B. mallei were almost ranged from 20-90 kDa. The charged strips with the equine sera panel containing immunoreactive protein antigens are shown in Fig. 2. P. aeruginosa and B. pseudomallei-mediated hyperimmune sera produced in albino rabbit showed no detectable bands pattern (Fig. 3).

**DISCUSSION**

Here, we describe an immunoblotting method based on the whole-cell proteome of B. mallei for serodiagnosis of glanders with a reliable sensitivity and specificity assessment of the immunoreactive proteins. The seroprevalence study was conducted among Iranian horses by using ELISA, CFT and also Western blot with combinations of B. mallei native strains. The ELISA and CFT false positives and distrustful sera were re-tested with Western blot and indicated considerable differences in specificity of serodiagnosis by the Western blot in comparison with the ELISA and CFT. Western blot assay confirmed positive and excluded false positive ELISA and CFT results with a 100% sensitivity and specificity. We know that the diagnosis of glanders is highly problematic due to low awareness of the clinical manifestations of disease, nonexistence of experience among microbiologists outside the endemic areas, lack of suitable culture media and identification systems in the custodian laboratories, and the biosafety facilities (10).

In an endemic area such as Iran, early detection of the disease would be helpful for controlling glanders by adopting the test and slaughter policy (3, 7). Currently, there is no effective vaccine against B. mallei. Thus, the only successful control option for glanders is testing and isolating positive cases (3). The effectiveness of diagnostic tests depends on their sensitivity and specificity, accuracy, predictive values, and field applicability. However, the efficiency of the tests can significantly improve by local strains for the glanders detection (17). Despite the importance of B. mallei as a hazardous zoonotic pathogen and potential bioweapon agent, little is known about the serodiagnosis of glanders. It is noteworthy that the
serological tests for RBPT, IHAT, CIET, and IFAT which are available for diagnosing glanders have also deficiencies and unacceptable specificity and/or sensitivity (18). Regarding the OIE recommendation, specific delayed hypersensitivity reaction following intracutaneous application of mallein as well as CFT has been used for the diagnosis of B. mallei infection (12, 19). Although CFT is an only available way to stop the establishment of B. mallei in niches and has formally been prescribed for the international trade of equidae, it has some shortcomings including insufficient sensitivity and specificity, improper results from sera having anticomplementary features as well as false positive/negative results (5, 15, 16). It has been reported that CFT in serodiagnosis of glanders in donkey, mule, and pregnant mare may give inconclusive results due to the anticomplementary activity of sera (19, 20). CFT may also lead to the destruction of some healthy animals due to the occurrence of false positives (17).

The whole-cell proteome-mediated immunoblotting can be adopted for new diagnostic target antigens existing in the serum. Furthermore, the method is highly specific test for sera with anticomplementary or suspicious reactions in CFT (21). In a recent study, the purified lipopolysaccharide (LPS) of B. mallei was made to diagnose positive and negative sera obtained from horses and mules from endemic and non-endemic areas by using the Western blot technique showing a significantly higher diagnostic specificity in comparison with the CFT particularly in glanders-free areas (15). However, many studies have believed that the extraction and purification of LPS from B. mallei are complicated, time-consuming, and unsafe for the laboratory. On the other hand, the LPS is a nonspecific antigen having common epitopes in many Gram-negative bacteria (16). B. mallei and B. pseudomallei have high cross-reactive epitopes in their LPS underlying false positive results in serodiagnosis (22). We assume the whole specific protein antigens assayed by the Western blot can detect the B. mallei-specific epitopes as well as genus-specific epitopes.

It is evident that there are difficulties in specific detection and differentiation of B. mallei and B. pseudomallei due to the derivation probability of B. mallei from an ancestral B. pseudomallei and having high similarity at their genome level (18). The other perspectives for the immunoserodiagnosis of B. mallei and B. pseudomallei using well-characterized single antigen by recombinant technology or naturally purified are discussed due to cross-reactivity chance (23). Our finding indicated that the whole specific immunoreactive protein antigens in glanders serodiagnosis overcome this shortcoming and showed no interference between B. mallei and B. pseudomallei. It is important in international trade of animals which have infections with dangerous zoonotic agents B. pseudomallei and/or B. mallei (3).

Preventing and controlling programs of glanders have been pointed out to health authorities in Iran (12). The illegal importation of B. mallei-infected horses from the neighboring countries can disseminate this disease (24). Moreover, the precious population of horses should be periodically checked for glanders. The healthy carriers (i.e., subclinically infected animals) should also be screened for controlling persistence and propagation of disease (12). The developed Western blot assay can be helpful in serodiagnosis of the healthy and suspicious horses in both glanders free and endemic regions with a high negative likelihood ratio for animal transport, international trade, and preparedness plans.

In conclusion, Western blotting is a highly suggestive confirmatory test along with the CFT to increase the serodiagnosis specificity of glanders. So, it can be scheduled as a trustworthy early serodiagnosis test in OIE Manual for eradication programs.

ACKNOWLEDGEMENTS

This work is a part of the Ph.D. thesis of the first author in the field of Microbiology and financially supported by the Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran. We are grateful to the Razi Vaccine and Serum Research Institute and department staff of Tuberculin/Mallein for the generous contribution.

REFERENCES

1. Smith ME, Gossman WG. Glanders And Melioidosis. [Updated 2018 Oct 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/28846298
2. Cárdenas NC, Galvis JOA, Farinati AA, Grisi-Filho JHH, Diehl GN, Machado G. Burkholderia mallei: The dynamics of networks and disease transmission. Transbound Emerg Dis 2019; 66:715-728.
3. Khan I, Wieler LH, Melzer F, Elschner MC, Muhammad G, Ali S, et al. Glanders in animals: a review on epidemiology, clinical presentation, diagnosis and countermeasures. Transbound Emerg Dis 2013; 60: 204-221.
4. Van Zandt KE, Greer MT, Gelhaus HC. Glanders: an overview of infection in humans. Orphanet J Rare Dis 2013; 8: 131.
5. Dohre SK, Kamthan A, Singh S, Alam SI, Kumar S. Identification of a new diagnostic antigen for glanders using immunoproteome analysis. Comp Immunol Microbiol Infect Dis 2017; 53: 26-32.
6. Hornstra H, Pearson T, Georgia S, Liguori A, Dale J, Price E, et al. Molecular epidemiology of glanders, Pakistan. Emerg Infect Dis 2009; 15: 2036-2039.
7. Khaki P, Mosavari N, Khajeh NS, Emam M, Ahouran M, Hashemi S, et al. Glanders outbreak at Tehran Zoo, Iran. Iran J Microbiol 2012; 4: 3-7.
8. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 2004; 54: 1134-1138.
9. Saqib M, Muhammad G, Naureen A, Hussain MH, Asi MN, Mansoor MK, et al. Effectiveness of an antimicrobial treatment scheme in a confined glanders outbreak. BMC Vet Res 2012; 8: 214.
10. Khan AS, Sage MJ. Centers for disease control and prevention. Biological and chemical terrorism: strategic plan for preparedness and response. Morb Mortal Wkyl Rep 2000; 49: 1-26.
11. Inglis TJ, Merritt AJ (2015). Burkholderia pseudomallei and Burkholderia mallei. In: Molecular Medi cal Microbiology. Ed, Y-W Tang, M Sussman, D Liu, I Poxtm, J Schwartzman. Academic Press, 2nd ed. 2015. Elsevier Ltd, London, UK, pp. 769-791.
12. OIE. World Organization for Animal Health [OIE]. Manual of diagnostic tests and vaccines for terrestrial animals. In Paris; 2018. Available from: http://www.oie.int/index.php?id=169&L=0&htm file=chapitre_glanders.htm
13. Naureen A, Saqib M, Muhammad G, Hussain MH, Asi MN. Comparative evaluation of Rose Bengal plate agglutination test, mallein test, and some conventional serological tests for diagnosis of equine glanders. J Vet Diagn Invest 2007; 19: 362-367.
14. Casey WT, McClean S. Exploiting molecular virulence determinants in Burkholderia to develop vaccine antigens. Curr Med Chem 2015; 22: 1719-1733.
15. Elschner MC, Scholz HC, Melzer F, Saqib M, Marten P, Rassbach A, et al. Use of a Western blot technique for the serodiagnosis of glanders. BMC Vet Res 2011; 7: 4.
16. Neubauer H, Sprague LD, Zacharia R, Tomaso H, Al Dahouk S, Wernery R, et al. Serodiagnosis of Burkholderia mallei infections in horses: state-of-the-art and perspectives. J Vet Med B Infect Dis Vet Public Health 2005; 52: 201-205.
17. Sprague LD, Zachariah R, Neubauer H, Wernery R, Joseph M, Scholz HC, et al. Prevalence-dependent use of serological tests for diagnosing glanders in horses. BMC Vet Res 2009; 5: 32.
18. Pal V, Kumar S, Malik P, Rai GP. Evaluation of recombinant proteins of Burkholderia mallei for serodiagnosis of glanders. Clin Vaccine Immunol 2012; 19: 1193-1198.
19. Malik P, Singha H, Goyal SK, Khurana SK, Tripathi BN, Dutt A, et al. Incidence of Burkholderia mallei infection among indigenous equines in India. Vet Rec Open 2015; 2(2): e000129.
20. Khan I, Wieler LH, Melzer F, Gwida M, Santana VL d. A, de Souza MMA, et al. Comparative evaluation of three commercially available complement fixation test antigens for the diagnosis of glanders. Vet Rec 2011; 169: 495.
21. Khan I, Elschner MC, Melzer F, Gwida M, Wieler LH, Ali R, et al. Performance of complement fixation test and confirmatory immunoblot as two-cascade testing approach for serodiagnosis of glanders in an endemic region of South East Asia. Berl Munch Tierarztl Wochenschr 2012; 125: 117-121.
22. Tamigney Kenfack M, Mazur M, Nualnou T, Shaffer TL, Ngassimou A, Blériot Y, et al. Deciphering minimal antigenic epitopes associated with Burkholderia pseudomallei and Burkholderia mallei lipopolysaccharide O-antigens. Nat Commun 2017; 8: 115.
23. Hatcher CL, Muruauto LA, Torres AG. Recent advances in Burkholderia mallei and B. pseudomallei research. Curr Trop Med Rep 2015; 2: 62-69.
24. Dominguez M, Münter mann S, de Guindos I, Timoney P. Equine disease events resulting from international horse movements: Systematic review and lessons learned. Equine Vet J 2016; 48: 641-653.